$1.480
+0.010 (+0.68%)終値時点
- High
- 1.500
- Open
- 1.480
- VWAP
- 1.48
- Vol
- 1.20M
- Mkt Cap
- 34.59M
- Low
- 1.445
- Amount
- 1.78M
- EV/EBITDA, TTM
- 0.22
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
バリュエーション指標
イベントタイムライン
ニュース
9.002-28NewsfilterAchilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration
9.002-06Business InsiderBiotech Alert: Searches spiking for these stocks today
8.512-24BenzingaAchilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
- 8.512-24Business Insider
Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock Up
- 8.512-24Newsfilter
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
ACHL FAQ — answered by Alphio AI
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。